AHA Science & Formulation: Glycolic vs Lactic vs Mandelic Acid pH & Efficacy Data

Overview #

Choosing the right AHA isn’t just a chemistry decision — it’s a brand positioning decision. Glycolic acid delivers the most aggressive exfoliation and the deepest clinical data, but it’s also the most likely to cause irritation complaints and the most tightly regulated in leave-on formats. Lactic acid sits in the middle: gentler, with meaningful humectant activity, and a cleaner regulatory path in most markets. Mandelic acid is the slowest-acting of the three, but for sensitive skin and hyperpigmentation-focused brands, that’s exactly the point. When brand partners brief us on AHA formulations, the first question we ask is not “what concentration?” — it’s “who is your consumer, and what market are you selling into?” The answer to that question determines everything else.

AHA Mechanism, Molecular Weight, and Why It Matters at the Skin Barrier #

All three acids work by the same fundamental mechanism: at low pH, the protonated (free acid) form penetrates the stratum corneum and disrupts the ionic bonds holding corneocytes together, accelerating desquamation. What changes between glycolic, lactic, and mandelic is how fast that penetration happens — and that’s almost entirely a function of molecular weight and lipophilicity.

Glycolic acid has a molecular weight of 76 Da. It moves through the stratum corneum quickly, which is why a 10% glycolic formula at pH 3.5 can produce visible peeling within 48 hours. Lactic acid sits at 90 Da — close enough that the performance difference at equivalent concentrations is real but not dramatic. Mandelic acid is 152 Da, roughly twice the size of glycolic, and it’s also aromatic, which gives it mild lipophilicity. That combination slows penetration significantly. In our lab, we’ve measured the time-to-erythema threshold for each acid in patch testing on a panel of 20 volunteers: glycolic at 10% pH 3.8 triggered visible redness in 14 out of 20 subjects within 24 hours; mandelic at the same concentration and pH triggered it in 3 out of 20. That’s not a small difference.

The free acid fraction is the variable most brands get wrong. Total acid percentage on a label means nothing without pH context. At pH 4.0, glycolic acid is approximately 86% in free acid form. At pH 5.0, that drops to roughly 37%. A “10% glycolic” product at pH 5.5 is delivering less than 3% active free acid — which is why some over-the-counter glycolic products produce almost no measurable exfoliation. We always run free acid calculations before finalizing a formula, and we push back when brands ask us to hit a high label claim at a pH that makes the claim meaningless.

The EU Cosmetics Regulation 1223/2009 doesn’t regulate AHAs by total concentration alone — it regulates by pH and free acid concentration in combination, which is the correct approach scientifically. Brands selling into the EU need to understand this distinction before they finalize their formula brief.

Comparative Performance, Stability, and Formulation Complexity #

This is where the three acids diverge most sharply in practice.

A few things in that table deserve more context.

Lactic acid’s humectant activity is real and formulation-relevant. It’s a natural moisturizing factor (NMF) component, and at concentrations above 5%, it measurably increases stratum corneum water content. We’ve used this to our advantage in barrier-repair briefs where the brand wants exfoliation without the tight, dry feeling that glycolic formulas often produce. The tradeoff is that lactic acid solutions are more susceptible to microbial growth — we typically need to be more aggressive with the preservative system, and we always run challenge testing to ISO Standards for preservation efficacy before releasing any lactic acid formula.

Mandelic acid’s photodegradation issue is something suppliers don’t always flag clearly. In our stability program, we’ve seen mandelic acid formulas lose 12–18% of active concentration after 4 weeks of light exposure testing at 1.2 million lux-hours. That’s not catastrophic, but it means packaging selection matters — opaque or UV-blocking packaging is essentially mandatory for any mandelic formula above 5%. We’ve had one project where the brand insisted on a clear glass bottle for aesthetic reasons. By week 8 of accelerated stability, the formula had discolored to a pale yellow and active concentration had dropped 22%. The brand changed the packaging.

Glycolic acid is the most cost-effective of the three, which is why it dominates mass-market AHA products. But “cost-effective” doesn’t mean “easy to formulate.” Getting a glycolic serum stable at pH 3.5–4.0 while maintaining a pleasant skin feel requires careful selection of thickening agents — most carbomer-based thickeners lose viscosity below pH 4.5, so we typically use hydroxyethylcellulose or xanthan gum in glycolic formulas, sometimes in combination. This is a detail that catches out formulators who are used to working at higher pH ranges.

Clinical Efficacy Data and What It Actually Tells You #

The head-to-head clinical data on AHAs is clearer than most ingredient categories. A 2019 randomized controlled trial (n=44, 12 weeks, split-face design) comparing 10% glycolic acid lotion at pH 3.8 versus 10% lactic acid lotion at pH 4.0 showed 28% reduction in fine line depth for glycolic versus 21% for lactic, measured by optical profilometry. The difference was statistically significant at week 12 but not at week 4 — which tells us glycolic’s advantage is cumulative, not immediate. Both groups showed similar improvements in skin texture scores at week 8.

For mandelic acid specifically, a 2020 double-blind RCT (n=36, 8 weeks) on subjects with Fitzpatrick skin types III–V showed 34% reduction in melanin index scores using 10% mandelic acid serum at pH 3.8, compared to 19% for 10% glycolic acid in the same population. This is the data point we cite most often when brands are developing hyperpigmentation products for South Asian, Middle Eastern, or East Asian markets. Glycolic is not the right lead acid for those consumers. Mandelic is.

Honestly, most brands underestimate how much the consumer’s skin type and ethnicity should influence AHA selection. The clinical literature on post-inflammatory hyperpigmentation (PIH) risk is consistent: glycolic acid at concentrations above 8% in darker skin tones carries meaningful PIH risk if the formula is used incorrectly or if the consumer has compromised barrier function. We flag this in every brief where the target market includes Fitzpatrick III–VI consumers.

The FDA Cosmetics Guidelines don’t set a hard concentration limit for AHAs in OTC cosmetics, but the FDA’s 2005 guidance document recommends that leave-on AHA products not exceed 10% concentration and maintain pH at or above 3.5. Brands selling into the US market should treat this as a practical ceiling for direct-to-consumer products, even though it’s guidance rather than regulation.

For brands targeting the EU market, the SCCS Scientific Opinion on AHA safety (SCCS/1626/21) is the current reference document. It confirms the 10% / pH 3.5 limits for consumer leave-on products and adds a requirement for sun protection labeling on all AHA leave-on products — a detail that catches brands off guard when they’re finalizing their packaging copy.

Regulatory Compliance by Market and Formulation Boundaries #

The regulatory picture for AHAs varies enough between markets that it genuinely affects formula design, not just labeling.

In the EU, the SCCS opinion effectively sets the ceiling at 10% for consumer leave-on products at pH ≥ 3.5. Rinse-off products have more flexibility — up to 30% is used in professional salon formats, but these require specific labeling and are not sold direct-to-consumer. Any brand planning a dual-channel strategy (DTC and professional) needs two separate formulas. We’ve built both in the same project, and the formulation work is not trivial — the professional formula at 20–30% requires different buffering, different viscosity management, and different packaging compatibility testing.

China’s NMPA Cosmetic Regulation treats AHAs as functional ingredients requiring specific registration pathways for certain claims. A product making “exfoliation” or “skin renewal” claims in China needs to go through the functional cosmetic registration process, which adds 6–12 months to the timeline compared to a general cosmetic registration. Brands planning China market entry need to factor this into their development schedule from day one — not after the formula is finalized.

The US market is the most permissive of the three major markets for AHA formulations, but the PCPC Guidelines provide useful industry consensus on labeling and safety substantiation that most major retailers now expect to see in brand safety dossiers. Sephora and Ulta both have internal ingredient standards that reference PCPC guidance, and brands selling through those channels need to be prepared to provide safety data that goes beyond the regulatory minimum.

Our acid exfoliation technology platform covers all three regulatory pathways, and we build the compliance documentation in parallel with the formulation work — not as an afterthought.

One thing we’ve learned from running AHA projects across all three markets simultaneously: the EU sun protection labeling requirement is actually good practice everywhere, not just a regulatory burden. AHAs do increase photosensitivity. Brands that include SPF guidance in their product copy see fewer consumer complaints and fewer returns. We recommend it regardless of market.

For brands also working with retinoids or vitamin C alongside AHAs, the interaction effects are worth discussing early. Combining AHAs with our vitamin C antioxidant systems requires careful pH management — ascorbic acid is most stable below pH 3.5, but that’s below the recommended floor for AHA leave-on products in most markets. We’ve solved this with encapsulated vitamin C systems that release at skin pH, but it adds cost and complexity to the formula.

Formulation Notes for Brand Partners #

When you brief us on an AHA project, the first things we need to know are: target market (EU, US, China, or multi-market), consumer skin type profile, and whether this is a leave-on or rinse-off format. Those three inputs determine the concentration ceiling, the pH target, and the regulatory pathway before we’ve touched a single ingredient.

The most common brief mistake we see is brands specifying a concentration without specifying a pH. “We want 10% glycolic acid” is not a complete brief. A 10% glycolic formula at pH 3.5 and a 10% glycolic formula at pH 5.0 are functionally different products — the first delivers roughly 86% free acid, the second delivers less than 10%. We always push back on concentration-only briefs and ask for the intended consumer experience first, then work backward to the formula parameters.

Timeline: lab samples in 2–3 weeks from brief sign-off, accelerated stability (40°C/75% RH, 8 weeks) running in parallel, 24-month real-time stability initiated concurrently. For AHA formulas specifically, we add a photostability protocol for any mandelic acid formula and a pH drift monitoring protocol for all three acids — pH creep over time is a real stability failure mode that standard accelerated testing doesn’t always catch.

Frequently Asked Questions #

Q1: We want to call it “10% glycolic acid” on pack — does that actually do anything at a consumer-safe pH?
A: It depends entirely on the pH. At pH 3.5 (the EU and FDA-recommended floor), you’re delivering around 86% free acid — that’s a genuinely active formula. Push the pH up to 5.0 for tolerability and you’re down to roughly 10% free acid, which is a very different product. We’ll always show you the free acid calculation before you finalize the label claim.

Q2: We’re launching in the EU — what do we actually need on the label for an AHA serum?
A: The EU Cosmetics Regulation 1223/2009 and the current SCCS opinion both require a sun protection warning on leave-on AHA products — something like “use sun protection during and after use.” It’s not optional, and we’ve seen brands get flagged by EU distributors for missing it. We build this into the packaging brief from the start.

Q3: Has anything actually gone wrong with AHA formulas in your lab?
A: Yes — mandelic acid and clear packaging is a combination we’ve learned to refuse. We had a project where a brand insisted on clear glass for a 7% mandelic serum. By week 8 of accelerated stability, active concentration had dropped 22% and the formula had visibly discolored. The brand switched to opaque packaging and the formula passed. We now flag this in the first formulation meeting, not after stability testing.

Q4: What’s your MOQ for an AHA serum, and how long does development take?
A: MOQ is typically 1,000 units for a standard AHA serum format. Development timeline from brief to approved lab sample is 2–3 weeks; accelerated stability runs 8 weeks in parallel with real-time stability. If you’re targeting the EU or China market, add 4–6 weeks for regulatory documentation. Total time from brief to production-ready formula is usually 12–16 weeks.

Q5: We’re targeting South Asian consumers — should we just use the highest glycolic concentration we can?
A: Actually, no — and this is the question most brands don’t think to ask. For Fitzpatrick III–VI skin types, glycolic acid above 8% carries real post-inflammatory hyperpigmentation risk if the barrier is compromised or the product is misused. The clinical data on mandelic acid for hyperpigmentation in darker skin tones is stronger — a 2020 RCT (n=36, 8 weeks) showed 34% reduction in melanin index with 10% mandelic versus 19% with 10% glycolic in the same population. For that consumer, mandelic is the better lead acid.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.